

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme.
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 21 NOV 13 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 22 NOV 20 CAS Registry Number crossover limit increased to 300,000 in
additional databases
NEWS 23 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased
to 50,000
NEWS 24 NOV 20 CA/CAplus patent kind codes will be updated
NEWS 25 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 26 DEC 11 CAS REGISTRY chemical nomenclature enhanced

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:46:41 ON 14 DEC 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:46:48 ON 14 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

DICTIONARY FILE UPDATES: 13 DEC 2006 HIGHEST RN 915360-23-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10798766\Struc 1.str



chain nodes :

7

ring nodes :

1 2 3 4 5 6 8 9 10 11 12

chain bonds :

4-7 6-8

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12

exact/norm bonds :

4-7 8-9 8-12 9-10 10-11 11-12

exact bonds :

6-8

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1

SAMPLE SEARCH INITIATED 08:47:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 371 TO ITERATE

100.0% PROCESSED 371 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01


10798766.trn

Page 4

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6265 TO 8575
PROJECTED ANSWERS: 656 TO 1544

L2 50 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\10798766\Struc 2.str




chain nodes :
7 13 14
ring nodes :
1 2 3 4 5 6 8 9 10 11 12
chain bonds :
4-7 6-8 10-13 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-12 9-10 10-11 11-12
exact/norm bonds :
4-7 8-9 8-12 9-10 10-11 11-12 13-14,
exact bonds :
6-8 10-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS

L3 STRUCTURE UPLOADED

=> d
L3 HAS NO ANSWERS
L3 STR

10798766.trn



Structure attributes must be viewed using STN Express query preparation.

=> 13

SAMPLE SEARCH INITIATED 08:48:30 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS 17 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 173 TO 747
 PROJECTED ANSWERS: 93 TO 587

L4 17 SEA SSS SAM L3

=> 13 full

FULL SEARCH INITIATED 08:48:34 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 502 TO ITERATE

100.0% PROCESSED 502 ITERATIONS 369 ANSWERS
 SEARCH TIME: 00.00.01

L5 369 SEA SSS FUL L3

=> file medline caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.82	168.03

FILE 'MEDLINE' ENTERED AT 08:48:40 ON 14 DEC 2006

FILE 'CAPLUS' ENTERED AT 08:48:40 ON 14 DEC 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> 15

10798766.trn

Page 6

L6 9 L5

=> dup rem l6

PROCESSING COMPLETED FOR L6

L7 9 DUP REM L6 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-9

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:656035 CAPLUS
 DOCUMENT NUMBER: 145:124595
 TITLE: Preparation of pyrrolylpyrimidines as selective inhibitors of erk protein kinase and uses thereof
 INVENTOR(S): Aronov, Alex; Hale, Michael R.; Maltais, Francois; Martinez-Botella, Gabriel; Straub, Judith; Tang, Qing
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006071644	A1	20060706	WO 2005-US46177	20051220
WO 2006071644	C1	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006160807 A1 20060720 US 2005-312618 20051220
 PRIORITY APPLN. INFO.: US 2004-638502P P 20041223

OTHER SOURCE(S): MARPAT 145:124595
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [X = Ph or 5-6-membered heterocycle; R1 = CN, halo, OH, etc.; R2 = H, halo, CO2H, CN, etc.; R3 and R4 independently = oxo, NO2, F, Cl, alkoxy, etc.; n = 0-4; p = 0-2], and their pharmaceutically acceptable salts, are prepared and disclosed as ERK2 inhibitors. Thus, e.g., II was prepared in a multi-step synthesis from 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethanone. I were evaluated for inhibition of ERK2, e.g., II was determined to possess a Ki value of $\leq 0.1 \mu\text{M}$. These compds., and pharmaceutically acceptable compns. thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferate disorders such as cancer.

IT 449732-19-8P 896720-20-0P 896720-21-1P

BEST AVAILABLE COPY

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 896720-22-2P 896720-23-3P 896720-24-4P
 896720-25-5P 896720-26-6P 896720-27-7P
 896720-28-8P 896720-29-9P 896720-30-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrrolylpyrimidines as selective inhibitors of erk protein kinase and uses thereof)
 RN 449732-19-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-20-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-4-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-21-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-4-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-22-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,4-dichlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-23-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-4-nitrophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-24-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-5-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-25-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dichlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-26-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-27-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,6-dichlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-28-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-6-methylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896720-29-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chlorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 896720-30-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1259560 CAPLUS
 DOCUMENT NUMBER: 144:7094
 TITLE: Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
 INVENTOR(S): Martinez-Botella, Gabriel; Hale, Michael R.; Maltais, Francois; Tang, Qing; Straub, Judith
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113546	A1	20051201	WO 2005-0516801	20050513
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2006058318	A1	20060316	US 2005-129114	20050513
PRIORITY APPLN. INFO.:			US 2004-571283P	P 20040514

OTHER SOURCE(S): MARPAT 144:7094
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Pyrrolylpyrimidine compds. [1 R1 = H, TCOR2, TCO2R2, TCOR2, TCO(CH2)NCO2R2, TCO(CH2)NCONR32, TCO(CH2)NCH2NR32, TPO2R22, provided that at least one R1 is not H; T = a valence bond or CR42O; R2 = R3 = H, (un)substituted C1-6 aliphatic group or (un)substituted 5-6 membered saturated, partially or fully unsatd. ring having 0-4 heteroatoms selected from N, O, S, or R3 = COR2, CO2R2, SO2R2, OR2, etc.; N = 0-6; Q = C1-10 alkylidene wherein 0-4 methylene units of Q replaced by O, NR4, S, SO, SO2, CO; R4 = H, or (un)substituted C1-6 aliphatic group] were prepared as prodrugs of ERK protein kinase inhibitors for the treatment of various diseases, conditions, or disorders. Thus, parent compound 4-(2-(1-(hydroxymethylpropylamino)-5-Me pyrimidin-4-yl)-1H-pyrrole-2-carboxylic

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 acid 1-(3-chlorophenyl)-2-hydroxyethyl]-amide was coupled with tert-butoxycarbonyl-N-Me valine to give after deprotection compd. II as hydrochloride salt and tested as pharmacokinetic.
 IT 869962-58-3P 869962-88-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 869962-58-3 CAPLUS
 CN Butanedioic acid, 1-[(2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-[(2S)-3-oxopropoxy)methyl](3-chlorophenyl)methyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-88-9 CAPLUS
 CN L-Valine, N-methyl-, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-[(2S)-3-methyl-2-(methylamino)-1-oxobutoxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl] ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

NHMe


• 3 HCl

IT 869962-37-8P 869962-38-9P 869962-39-OP
 869962-40-3P 869962-41-4P 869962-46-9P
 869962-47-OP 869962-48-1P 869962-49-2P
 869962-87-8P 869962-89-OP 869962-90-3P
 869962-91-4P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)
 RN 869962-37-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[[[(1S)-2-(acetyloxy)-1-(3-chlorophenyl)ethyl]-4-[2-[[[(1S)-1-(acetyloxy)methyl]propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10798766.trn

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-38-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[[(1S)-1-(acetyloxy)methyl]propyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-39-0 CAPLUS
 CN Carbonic acid, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-40-3 CAPLUS
 CN Propanoic acid, 2-methyl-, (2S)-2-[(4-{5-methyl-2-[(1S)-1-[(2-methyl-1-oxopropoxy)methyl]propyl]amino}-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonylamino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-41-4 CAPLUS
 CN Carbonic acid, (2S)-2-[(4-{5-[(1S)-1-(3-chlorophenyl)-2-[(ethoxycarbonyloxy)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



RN 869962-47-0 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, (2S)-2-[(4-{5-[(1S)-1-(3-chlorophenyl)-2-[(2,2-dimethyl-1-oxopropoxy)methyl]methyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-46-9 CAPLUS
 CN L-Valine, (2S)-2-[(4-{5-[(1S)-2-[(2S)-2-amino-3-methyl-1-oxobutoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-48-1 CAPLUS
 CN Propanoic acid, 2-methyl-, (2S)-2-[(4-{5-[(1S)-1-(3-chlorophenyl)-2-[(ethoxycarbonyloxy)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-49-2 CAPLUS
 CN Phosphoric acid, (2S)-2-[(4-{5-[(1S)-1-(3-chlorophenyl)-2-[(hydroxyethyl)amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-87-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-2-(acetyloxy)-1-(3-chlorophenyl)ethyl]-4-
 [2-[[1(1S)-1-[(acetyloxy)methyl]propyl]amino]-5-methyl-4-pyrimidinyl]-,
 monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 869962-89-0 CAPLUS
 CN Acetic acid, (2-methoxyethoxy)-, (2S)-2-[[[4-[5-[[1(1S)-3-(3-chlorophenyl)-1,6-dioxo-5,8,11-trioxo-2-azadodec-1-yl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, monomethanesulfonate (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

NH2

● 3 HCl

RN 869962-91-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-(phosphonoxy)ethyl]-4-[5-methyl-2-[[[1(1S)-1-[(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl]-, monosodium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 869962-61-8
 CMF C32 H42 Cl N5 O9

Absolute stereochemistry.



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 869962-90-3 CAPLUS
 CN L-Alanine, (2S)-2-[[[4-[5-[[[1(1S)-2-[(2S)-2-amino-1-oxopropoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

IT 869962-42-5P 869962-43-6P 869962-44-7P
 869962-45-8P 869962-50-5P 869962-53-8P
 869962-56-1P 869962-57-2P 869962-59-4P
 869962-60-7P 869962-61-8P 869962-62-9P
 869962-63-0P 869962-64-1P 869962-66-1P
 869962-67-4P 869962-69-6P 869962-70-9P
 869962-72-1P 869962-73-2P 869962-74-3P
 869962-76-5P 869962-77-6P 869962-79-8P
 869962-80-1P 869962-81-2P 869962-82-3P
 869962-83-4P 869962-84-5P 869962-85-6P
 869962-86-7P 869962-92-5P 869962-93-6P
 869962-94-7P 869962-95-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)

RN 869962-42-5 CAPLUS
 CN Carbonic acid, (2S)-2-(3-chlorophenyl)-2-[[[4-[5-methyl-2-[[[1(1S)-1-[[[phenylmethoxy]carbonyl]oxy]methyl]propyl]amino]-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 869962-43-6 CAPLUS

CN Phosphoric acid, (2S)-2-(3-chlorophenyl)-2-[[[4-[2-[[[(1S)-1-

[[[diethoxyphosphinyl]oxy]methyl]propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-44-7 CAPLUS

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 869962-50-5 CAPLUS

CN Carbonic acid, (2S)-2-(3-chlorophenyl)-2-[[[4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-53-8 CAPLUS

CN Acetic acid, (2-methoxyethoxy)-, (2S)-2-[[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-56-1 CAPLUS

CN Acetic acid, [2-(2-methoxyethoxy)ethoxy]-, (2S)-2-[[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Carbonic acid, (2S)-2-[[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-[[[(1-methylethoxy)carbonyl]oxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-45-8 CAPLUS

CN Carbonic acid, (2S)-2-[[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl 1-methylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869962-57-2 CAPLUS

CN Propanoic acid, 2,2-dimethyl-, (2S)-2-[[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869962-59-4 CAPLUS

CN L-Valine, 3-methyl-, (2S)-2-[[[4-[5-[[[(1S)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10798766.trn

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 1-A

NH₂

RN 869962-60-7 CAPLUS

CN L-Valine, N-methyl-, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-[(2S)-3-methyl-2-(methylamino)-1-oxobutoxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 2-A

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 1-A



NHMe

RN 869962-61-8 CAPLUS


CN Acetic acid, (2-methoxyethoxy)-, (2S)-2-[[4-[5-[[[(3S)-3-(3-chlorophenyl)-1,6-dioxo-5,8,11-trioxo-2-azadodec-1-yl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)




RN 869962-62-9 CAPLUS

CN L-Alanine, (2S)-2-[[4-[5-[[[(1S)-2-[(2S)-2-amino-1-oxopropoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

(Continued)

PAGE 2-A




RN 869962-63-0 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[[[(1S)-1-(3-chlorophenyl)-2-

(phosphonoxy)ethyl]-4-[5-methyl-2-[[[(1S)-1-[(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869962-64-1 CAPLUS


CN 4-Morpholinebutanoic acid, γ-oxo-, (2S)-2-(3-chlorophenyl)-2-[[[4-[5-

methyl-2-[[[(1S)-1-[[4-(4-morpholinyl)-1,4-dioxobutoxy]methyl]propyl]amino]-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 869962-66-3 CAPLUS
 CN L-Isoleucine, (2S)-2-[[4-[5-[[[(1S)-2-[[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 869962-69-6 CAPLUS
 CN L-Leucine, (2S)-2-[[4-[5-[[[(1S)-2-[[[(2S)-2-amino-4-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A


NH2

RN 869962-67-4 CAPLUS
 CN L-Leucine, N-methyl-,
 (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-[[[(2S)-4-methyl-2-(methylamino)-1-oxopentyl]oxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

NH2

RN 869962-70-9 CAPLUS
 CN L-Proline, (2S)-2-[[4-[5-[[[(1S)-2-[[[(2S)-2-amino-4-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B




RN 869962-72-1 CAPLUS

CN Alanine, 2-methyl-, (2S)-2-[[4-[5-[[[(1S)-2-(2-amino-2-methyl-1-oxopropoxy)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 2-A




L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-76-5 CAPLUS

CN L-Valine, N-methyl-, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869962-77-6 CAPLUS

CN L-Valine, N-methyl-, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10798766.trn

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 869962-73-2 CAPLUS

CN L-Valine, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-74-3 CAPLUS

CN L-Valine, (2S)-2-[[4-[5-[[[(1S)-1-(3-chlorophenyl)-2-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 869962-79-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-

(phosphonoxy)ethyl]-4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-80-1 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-(hydroxymethyl)-4-[5-methyl-2-[[[(1S)-1-(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 869962-81-2 CAPLUS
 CN L-Valine, (2S)-2-[[[4-[2-[[[(1S)-1-[(acetyloxy)methyl]propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]-2-(3-chlorophenyl)ethyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-82-3 CAPLUS
 CN L-Valine, (2S)-2-[[[4-[5-[[[(1S)-2-(acetyloxy)-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl]ester (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 869962-84-5 CAPLUS
 CN Alanine, 2-methyl-, (2S)-2-(3-chlorophenyl)-2-[[[4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-85-6 CAPLUS
 CN Alanine, N,2-dimethyl-, (2S)-2-(3-chlorophenyl)-2-[[[4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 869962-83-4 CAPLUS
 CN Alanine, 2-methyl-, (2S)-2-(3-chlorophenyl)-2-[[[4-[5-methyl-2-[[[(1S)-1-[(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl]ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 869962-86-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[[[(1S)-2-(acetyloxy)-1-(3-chlorophenyl)ethyl]-4-[5-methyl-2-[[[(1S)-1-[(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl]-5-methyl-2-pyrimidinyl]amino]ethyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 869962-86-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[[[(1S)-2-(acetyloxy)-1-(3-chlorophenyl)ethyl]-4-[5-methyl-2-[[[(1S)-1-[(phosphonoxy)methyl]propyl]amino]-4-pyrimidinyl]-5-methyl-2-pyrimidinyl]amino]ethyl]ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869962-92-5 CAPLUS
 CN Butanedioic acid, 1-[[[(2S)-2-[[[4-[5-[[[(1S)-1-[(3-carboxy-1-oxopropoxy)methyl]-(3-chlorophenyl)methyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl]ester, disodium salt (9CI) (CA INDEX NAME)

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 869962-93-6 CAPLUS
CN L-Isoleucine, (2S)-2-[[4-[5-[[[(1S)-2-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]oxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



NH2

3 HCl


RN 869962-94-7 CAPLUS
CN L-Valine, (2S)-2-[[4-[5-[[[(1S)-2-[(2S)-2-amino-3-methyl-1-oxobutoxy]-1-(3-chlorophenyl)ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 2-A

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



NH2


3 HCl

RN 869962-95-8 CAPLUS
CN L-Proline, (2S)-2-[3-chlorophenyl]-2-[[4-[5-methyl-2-[[[(1S)-1-[[[(2S)-2-pyrrolidinylcarbonyl]oxy]methyl]propyl]amino]-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



HCl


PAGE 1-B



IT 449732-51-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)
RN 449732-51-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide,
N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 869962-96-9P 869962-97-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of prodrugs of pyrrolylpyrimidine peptidomimetics as ERK protein kinase inhibitors for treating of cancer and other diseases, conditions, or disorders)
 RN 869962-96-9 CAPLUS
 CN L-Valine, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-, (2S)-2-[[4-[[[(1S)-1-(3-chlorophenyl)-2-[(2S)-2-[(1,1-dimethylethoxy)carbonyl]methylamino]-3-methyl-1-oxobutoxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 869962-97-0 CAPLUS
 CN L-Isoleucine, N-[(1,1-dimethylethoxy)carbonyl]-, (2S)-2-[[4-[[[(1S)-1-(3-chlorophenyl)-2-[[[(2S,3S)-2-[(1,1-dimethylethoxy)carbonyl]amino]-3-methyl-1-oxopentyl]oxy]ethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]amino]butyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:799581 CAPLUS
 DOCUMENT NUMBER: 141:314342
 TITLE: Preparation of substituted pyrroles, particularly pyrimidinylpyrrolicarboxylic acid esters and amides, as inhibitors of protein kinases such as ERK2, JNK3, Src kinase, Aurora2, and GSK3
 INVENTOR(S): Maltais, Francois; Aronov, Alex; Hale, Michael R.; Moon, Young-choon
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 84 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083203	A1	20040930	WO 2004-US7540	20040311
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004221881	A1	20040930	AU 2004-221881	20040311
CA 2522176	AA	20040930	CA 2004-2522176	20040311
US 2004220200	A1	20041104	US 2004-798766	20040311
EP 1606284	A1	20051221	EP 2004-719833	20040311
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
JP 2006520386	T2	20060907	JP 2006-507111	20040311
PRIORITY APPLN. INFO.:			US 2003-454405P	P 20030313
			WO 2004-US7540	W 20040311

OTHER SOURCE(S): MARPAT 141:314342
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Comps. I [A = a pyrrole ring substituted with two R_y groups and QR2 and optionally substituted at the 1-position with R_z; Q = bond, (un)substituted carbonylamino, sulfonylamino, sulfonyl, aminocarbonylamino, aminocarbonyl, aminosulfonyl, aminosulfonylamino, aminocarbonyloxy, carbonyl, carbonyloxy; R1 = NC, halo, alkoxy or aryloxy, alkylthio or arylthio, (un)substituted amino, R4: R2 = halogen, NC, (un)substituted alkyl; R3 = H, (un)substituted alkyl, aryl; R4 = R6, R6C(=O), R6O2C, R6NC(=O), R6SO2; R6 = alkyl or aryl; R_x = alkyl, halogen.


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-11-6 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid,
 4-[2-[[4-(1-fluorophenyl)amino]-4-pyrimidinyl]-
 5-methyl-3-phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-12-7 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid,
 4-[2-[[3-chlorophenyl]amino]-4-pyrimidinyl]-
 5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-13-8 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid,
 4-[2-[[3-methoxyphenyl]amino]-4-pyrimidinyl]-
 5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-17-2 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[[4-(aminosulfonyl)phenyl]amino]-4-
 pyrimidinyl]-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-18-3 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[[6-chloro-3-pyridinyl]amino]-4-
 pyrimidinyl]-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-19-4 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid,
 4-[2-[[3-chlorophenyl]amino]-4-pyrimidinyl]-
 3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-14-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-methyl-3-phenyl-4-[2-[[3-(
 phenylmethoxy)phenyl]amino]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-15-0 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[[6-chloro-3-pyridinyl]amino]-4-
 pyrimidinyl]-5-methyl-3-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-16-1 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-(phenylamino)-4-
 pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-20-7 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid,
 4-[2-[[3-methoxyphenyl]amino]-4-pyrimidinyl]-
 3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-21-8 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[2-[[3-(
 phenylmethoxy)phenyl]amino]-4-pyrimidinyl]-, 1,1-dimethylethyl ester
 (9CI) (CA INDEX NAME)




RN 766522-22-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[2-amino-4-pyrimidinyl]-3,5-dimethyl-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-23-0 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 3,5-dimethyl-4-[(2-methylamino)-4-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-24-1 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[(2-ethylamino)-4-pyrimidinyl]-3,5-dimethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 766522-25-2 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[(2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl)-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-29-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-[(4-chloro-2-fluorophenyl)amino]-5-hydroxy-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 766522-31-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[(5-cyano-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-26-3 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[(2-(cyclohexylamino)-4-pyrimidinyl)-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 766522-27-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-amino-1-(3-chlorophenyl)ethyl]-4-[(2-amino-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 766522-28-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-amino-1-(3-chlorophenyl)ethyl]-4-[(5-fluoro-2-[(3,3,3-trifluoro-1-hydroxypropyl)amino]-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 766522-32-1 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[(5-cyano-2-(phenylamino)-4-pyrimidinyl)-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-33-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-4-pyrimidinyl)-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-34-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-fluoro-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 766522-35-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-37-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(ethoxyamino)-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 766522-38-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S,2R)-2-hydroxycyclohexyl]-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-42-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S,2R)-2-hydroxycyclohexyl]-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-43-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-(cis-4-hydroxycyclohexyl)-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 766522-44-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-(2-hydroxy-2-phenylethyl)-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-39-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 766522-40-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-(2,3-dihydro-1H-inden-2-yl)-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 766522-41-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-cyclopropyl-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-45-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[1-(hydroxymethyl)cyclopentyl]-3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 766522-46-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 766522-47-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 3,5-dimethyl-4-[2-(phenylamino)-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-48-9 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[[4-(aminosulfonyl)phenyl]amino]-5-(hydroxymethyl)-4-pyrimidinyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-49-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 766522-51-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 766522-54-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3-(hydroxymethyl)-5-methyl-4-[2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-55-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-fluoro-4-pyrimidinyl)-3-[[dimethylamino]methyl]-N-[(4-fluorophenyl)methyl]-5-methyl- (9CI) (CA INDEX NAME)



10798766.trn


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dimethyl-4-[2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 766522-52-5 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 766522-53-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-[[[(1S)-1-(hydroxymethyl)propyl]amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 766522-56-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]-5-methyl-3-[(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 766522-57-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-5-(hydroxymethyl)-3-methyl-4-[2-[(2,2,2-trifluoroethoxy)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 766522-58-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-(fluoro-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl)-3,5-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-59-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[(5-
 (hydroxymethyl)-2-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]-3,5-dimethyl-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 766522-60-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[(5-
 (hydroxymethyl)-2-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]-3,5-
 dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 766522-62-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-chloro-4-fluorophenyl)amino]-4-
 pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3,5-dimethyl-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 766522-69-4 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid,
 4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-4-
 pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2004:546415 CAPLUS
 DOCUMENT NUMBER: 141:89104
 TITLE: Preparation of 2-substituted 4-heteroarylpyrimidines
 as GSK3 inhibitors for the treatment of diabetes
 INVENTOR(S): Wang, Shudong; Meades, Christopher; Wood, Gavin;
 Duncan, Kenneth; Zhevela, Daniella; Fischer, Peter
 PATENT ASSIGNEE(S): Cyclacel Limited, UK
 SOURCE: PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056368	A1	20040708	WO 2003-GB5558	20031218
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			
TG:	CA 2502138	AA	20040708	CA 2003-2502138
AU 2003292444	A1	20040714	AU 2003-292444	20031218
EP 1572211	A1	20050914	EP 2003-768023	20031218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003016703	A	20051018	BR 2003-16703	20031218
CN 1720049	A	20060111	CN 2003-80104697	20031218
JP 2005515588	T2	20060601	JP 2004-561646	20031218
US 2005282843	A1	20051222	US 2005-140136	20050526
PRIORITY APPLN. INFO.:			GB 2002-29581	A 20021219
			WO 2003-GB5558	W 20031218


OTHER SOURCE(S): MARPAT 141:89104
 GI



L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB Heteroarylpyrimidines of formula I (X, Y = S, (substituted) N, (substituted) C; R1 = alkyl, aryl, heteroaryl, halo, CF3, CN, (substituted) NH2, alkoxy, carbonyl, etc.; R2-R4 = H, alkyl, aryl, heteroaryl, halo, CF3, NO2, OH, alkoxy, acyl, alkoxy, carbonyl, (substituted) NH2, SO2-alkyl, etc.) are prepared for use in a medicament for treating diabetes. The compds. of the invention also have applications in the treatment of CNS disorders, alopecia, cardiovascular disorders and stroke. Thus, II was prepared, and had IC50 of 0.005 µM against GSK3β.
 IT 467470-28-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroarylpyrimidines as GSK3 inhibitors)
 RH 467470-28-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:581038 CAPLUS
 DOCUMENT NUMBER: 141:260690
 TITLE: Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidine CDK inhibitors
 AUTHOR(S): Wang, Shudong; Wood, Gavin; Meades, Christopher; Griffiths, Gary; Midgley, Carol; McNaee, Iain; McInnes, Campbell; Anderson, Sian; Jackson, Wayne; Mezna, Mokdad; Yuill, Rhoda; Walkinshaw, Malcolm; Fischer, Peter M.
 CORPORATE SOURCE: Cyclacel Limited, James Lindsay Place, Dundee, DD1 5JJ, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(16), 4237-4240
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:260690
 GI



AB A series of 2-anilino-4-(1H-pyrrol-3-yl)pyrimidines were prepared and evaluated for their ability to inhibit cyclin-dependent kinases (CDKs).
 A number of analogs, e.g., I, were found to be potent CDK2 and CDK4 inhibitors and to exhibit anti-proliferative activity against human tumor cell lines.
 Structure-activity relationships and biochem. characterization are presented.
 IT 467470-28-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation, kinase inhibition, and anti-proliferative activity of anilino(dimethylpyrrolyl)pyrimidines via cyclocondensation of phenylguanidines with dimethylpyrrolyl-enaminones)
 RH 467470-28-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dimethyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:875281 CAPLUS
 DOCUMENT NUMBER: 139:364952
 TITLE: Preparation of pyrrole derivatives as inhibitors of ERK2
 INVENTOR(S): Hale, Michael R.; Maltais, Francois; Tang, Qing; Straub, Judith; Aronov, Alexander
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003091246	A1	20031106	WO 2003-US13186	20030425
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, T2, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003237121	A1	20031110	AU 2003-237121	20030425
US 2004029857	A1	20040212	US 2003-424280	20030425
EP 1506189	A1	20050216	EP 2003-736503	20030425
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005234059	A1	20051020	US 2005-77188	20050310
PRIORITY APPLN. INFO.:			US 2002-376259P	P 20020426
			US 2002-403853P	P 20020814
			US 2003-424280	A3 20030425
			WO 2003-US13186	W 20030425

OTHER SOURCE(S): MARPAT 139:364952
 GI



L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Pyrroles I [A1, A2 = N, (un)substituted CH; T = bond, (un)substituted CH2, CO, COCO, CONH, CONHNH, CO2, O2C, NHCO, O, NHCONH, O2CNH, NHHN, NHCO2, S, S(O), SO2, NH, SO2NH, NHSO2, NH2SO2NH; X = CO, (un)substituted CONH, NHCO, NHSO2, SO2NH, S(O), SO2; R1 = H, CN, halogen, (un)substituted NH2, OH, aliphatic, cycloaliph., aromatic, heterocyclic, heteroarom.; R2 = (un)substituted alkyl, NH2, ONH2, NHOH, OH, CO2H, SH, NHCONH2, CONH2, SO2H, NHSO2H, SO2NH2, acyl, aliphatic, cycloaliph., aromatic, heterocyclic, heteroarom.; R3 = aliphatic, cycloaliph., aromatic, heterocyclic, heteroarom., (un)substituted OH, SH, S(O)H, SO2H, ONH2, NH2, NHHN2, NHOH; R4 = H, (un)substituted aliphatic, CO2H, SO2H, acyl; R5, R6 = CN, NO2, halogen, (un)substituted NH2, SH, OH, aliphatic] were prepared. The compds. are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases for treating diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease. Thus, 2-trichloroacetylpyrrole was converted to the 4-(3-methoxypropionyl) derivative and then to the amide with (S)-phenylglycinol. The amide was treated with Brederick's reagent and cyclized with benzamidine to give I [A1 = N, A2 = CH, T = bond, R1 = Me, R3 = Ph, R4-R6 = H, XR2 = (S)-CONHCHPhCH2OH, I1]. I1 had Ki < 0.1 μ M for inhibition of ERK2.


IT 620615-80-7P 620615-81-8P 620615-82-9P 620615-83-0P 620615-84-1P 620615-85-2P 620615-86-3P 620615-87-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [preparation of pyrrole derivs. as inhibitors of ERK2]


RN 620615-80-7 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-[(3-(trifluoromethyl)phenyl)ethyl]-4-[5-methyl-2-(trimethylhydrazino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 620615-84-1 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2-hydroxyethoxy)methylamino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 620615-85-2 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2-hydroxyethoxy)methylamino]-4-pyrimidinyl]-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 620615-81-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[5-methyl-2-(trimethylhydrazino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 620615-82-9 CAPLUS

CN 1H-Pyrrole-2-carboxamide, 4-[5-chloro-2-(trimethylhydrazino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 620615-83-0 CAPLUS

CN Acetic acid, 2-[5-chloro-4-[5-[[[(1S)-2-hydroxy-1-phenylethylamino]carbonyl]-1H-pyrrol-3-yl]-2-pyrimidinyl]-1,2-dimethylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 620615-86-3 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-[(2-hydroxyethoxy)methylamino]-4-pyrimidinyl]-1-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 620615-87-4 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-3-methyl-4-[2-(trimethylhydrazino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:849586 CAPLUS
DOCUMENT NUMBER: 137:370099
TITLE: Preparation of 3-aminopyrazolo[3,4-c]pyridazines as inhibitors of glycogen synthase kinase-3 and crystal structures of gsk-3 β protein and protein complexes
INVENTOR(S): Ter Haar, Ernst; Swenson, Lovorka; Green, Jeremy; Arnott, Michael J.
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 778 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088078	A2	20021107	WO 2002-US13511	20020429
WO 2002088078	A3	20040506		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2444882	AA	20021107	CA 2002-2444882	20020429
AU 2002259071	A1	20021111	AU 2002-259071	20020429
US 2003125332	A1	20030703	US 2002-135255	20020429
EP 1435957	A2	20040714	EP 2002-729056	20020429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2005504731	T2	20050217	JP 2002-585380	20020429
PRIORITY APPLN. INFO.:			US 2001-287366P	P 20010430
			US 2001-297094P	P 20010608
			US 2002-361899P	P 20020227
			WO 2002-US13511	W 20020429

OTHER SOURCE(S): MARPAT 137:370099
GI

L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. [I: R1 = H, RCO, RO2C, (substituted) alipharyl, carbocyclyl, heterocyclyl, heteroaryl, etc.; R2, R3 = H, (substituted) alipharyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, NR2, NRCOR, SR, OR, CF3, halo, NO2, cyano, etc.; R = H, (substituted) alipharyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl], were prepared thus,
3-chloro-4-cyano-5,6-diphenylpyridazine
was refluxed with N2H4 in EtOH to give 3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine. The latter inhibited gsk-3 with Ki50.1 μ M.
IT 474381-76-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(crystal structure determination; preparation of pyrazolo[3,4-c]pyridazines as inhibitors of gsk-3 and crystal structures of gsk-3 β protein and protein complexes)
RN 474381-76-5 CAPLUS
CN Kinase (phosphorylating), glycogen synthetase (human isoenzyme 3 β), compd. with N-(2-hydroxy-1-phenylethyl)-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]-1H-pyrrole-2-carboxamide (1:1) (9C1) (CA INDEX NAME)
CM 1
CRN 474381-75-4
CMF C24 H23 N5 O2



CM 2
CRN 474231-10-2
CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:777930 CAPLUS
DOCUMENT NUMBER: 137:294968
TITLE: Preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer
INVENTOR(S): Fischer, Peter Martin; Wang, Shudong; Wood, Gavin
PATENT ASSIGNEE(S): Cyclacel Limited, UK
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079193	A1	20021010	WO 2002-GB1445	20020326
WO 2002079193	C1	20050317		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2440228	AA	20021010	CA 2002-2440228	20020326
EP 1373253	A1	20040102	EP 2002-718319	20020326
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002008447	A	20040302	BR 2002-8447	20020326
CN 1503794	A	20040609	CN 2002-807553	20020326
JP 2004538260	T2	20041224	JP 2002-577818	20020326
NZ 528347	A	20050729	NZ 2002-528347	20020326
GB 2375534	A1	20021120	GB 2002-7229	20020327
GB 2375534	B2	20030924		
US 2004132746	A1	20040708	US 2003-671747	20030924
PRIORITY APPLN. INFO.:			GB 2001-7901	A 20010329
			WO 2002-GB1445	W 20020326

OTHER SOURCE(S): MARPAT 137:294968
GI


L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I: one of X1 and X2 = NR10 and the other of X1 and X2 =

CR9; Z = NH, NHCO, NHSO2, etc.; R1-R3, R9, R10 = H, alkyl, aryl, etc.; R4-R8 = H, alkyl, halo, etc.; with the proviso], useful as inhibitors of cyclin-dependent kinases (CDKs) and hence useful in the treatment of proliferation disorders such as cancer, leukemia, psoriasis and the like, were prepared. Thus, heating 3-dimethylamino-1-(2,4-dimethyl-1H-pyrrol-3-yl)propanone (preparation given) with 4-fluorophenyl guanidine nitrate in the presence of NaOH in 2-methoxyethanol at 100-120°C under N2 for 6 h afforded 62% II which showed IC50 of 1.0±0.7 μM against CDK2/cyclin E.

IT 467470-28-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate: preparation of 4-(1H-pyrrolyl)pyrimidin-2-ylamines as inhibitors of cyclin dependent kinases for treating cancer)
 RN 467470-28-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]-3,5-dimethyl- (9C1) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN


ACCESSION NUMBER: 2002:637673 CAPLUS
 DOCUMENT NUMBER: 137:185518
 TITLE: Pyrimidine derivatives as ERK2 inhibitors
 INVENTOR(S): Cao, Jingrong; Green, Jeremy; Hale, Michael; Maltais, Francois; Straub, Judy; Tang, Qing; Aronov, Alex
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 188 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064586	A2	20020822	WO 2002-US3791	20020208
WO 2002064586	A3	20030206		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2437767	AA	20020822	CA 2002-2437767	20020208
US 2003092714	A1	20030515	US 2002-71699	20020208
US 6743791	B2	20040601		
EP 1363906	A2	20031126	EP 2002-724922	20020208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002007114	A	20040225	BR 2002-7114	20020208
HU 200304052	A2	20040428	HU 2003-4052	20020208
CN 1494541	A	20040505	CN 2002-805766	20020208
JP 2004520402	T2	20040708	JP 2002-564517	20020208
NZ 527251	A	20060929	NZ 2002-527251	20020208
ZA 2003005799	A	20040728	ZA 2003-5799	20030728
NO 2003003491	A	20031008	NO 2003-3491	20030806
US 2004229875	A1	20041118	US 2004-770814	20040203
AU 2006202623	A1	20060713	AU 2006-202623	20060620
PRIORITY APPLN., INFO.:			US 2001-267818P	P 20010209
			US 2001-328768P	P 20011012
			AU 2002-255521	A3 20020208
			US 2002-71699	A3 20020208
			WO 2002-US3791	W 20020208

OTHER SOURCE(S): MARPAT 137:185518
 GI

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Pyrimidines I [Z1, Z2 = N, CH; X = 5-membered heteroarom. ring to which
 OR2 is attached in the 3-position relative to the pyrimidine ring attachment; T, O = linker group; U = NR4, NR4CO, NR4CONR4, NR4CO2, O, CONR4, CO, CO2, O2C, NR4SO2, SO2NR4, NR4SO2NR4, SO2; m, n = 0, 1; R1 = CN, halogen, NR42, (un)substituted OH; R2 = (un)substituted alkyl, NH2; R3 = H, (un)substituted alkyl, CN; R4 = H, (un)substituted alkyl; NR42 = heterocyclic] were prepared for use as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease. Thus, the pyrimidine II was obtained by cyclizing the 3-dimethylamino-2-methylacryloylpyrrole fragment with (S)-HOCH2CHPhNHC(=NH)NH2. II had ki < 0.1 μM for inhibition of ERK2 in vitro.

IT 449731-36-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrimidine deriva. as ERK2 inhibitors)
 RN 449731-36-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9C1) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 449730-22-7P 449730-23-8P 449730-24-9P
 449730-25-0P 449730-26-1P 449730-27-2P
 449730-28-3P 449730-29-4P 449730-30-7P
 449730-31-8P 449730-32-9P 449730-33-0P
 449730-34-1P 449730-35-2P 449730-36-3P
 449730-37-4P 449730-38-5P 449730-39-6P
 449730-40-9P 449730-41-0P 449730-42-1P
 449730-43-2P 449730-44-3P 449730-45-4P
 449730-46-5P 449730-47-6P 449730-48-7P
 449730-49-8P 449730-50-1P 449730-51-2P
 449730-52-3P 449730-53-4P 449730-54-5P
 449730-55-6P 449730-56-7P 449730-57-8P
 449730-59-0P 449730-60-3P 449730-61-4P
 449730-62-5P 449730-63-6P 449730-64-7P
 449730-65-8P 449730-66-9P 449730-67-0P
 449730-68-1P 449730-69-2P 449730-70-5P
 449730-71-6P 449730-72-7P 449730-73-8P
 449730-74-9P 449730-75-0P 449730-76-1P
 449730-77-2P 449730-78-3P 449730-79-4P
 449730-80-7P 449730-81-8P 449730-82-9P
 449730-83-0P 449730-84-1P 449730-85-2P
 449730-86-3P 449730-87-4P 449730-88-5P
 449730-89-6P 449730-90-9P 449730-91-0P
 449731-00-4P 449731-19-5P 449731-20-8P
 449731-21-9P 449731-22-0P 449731-23-1P
 449731-24-2P 449731-26-4P 449731-30-0P
 449731-31-1P 449731-33-3P 449731-35-5P
 449731-39-9P 449731-40-2P 449731-41-3P
 449731-42-4P 449731-43-5P 449731-44-6P
 449731-50-4P 449731-51-5P 449731-52-6P
 449731-53-7P 449731-54-8P 449731-56-0P
 449731-57-1P 449731-58-2P 449731-59-3P
 449731-60-6P 449731-62-8P 449731-63-9P
 449731-64-0P 449731-65-1P 449731-66-2P
 449731-67-3P 449731-68-4P 449731-69-5P
 449731-70-8P 449731-71-9P 449731-72-0P
 449731-73-1P 449731-74-2P 449731-75-3P
 449731-76-4P 449731-77-5P 449731-78-6P
 449731-79-7P 449731-80-0P 449731-81-1P
 449731-83-3P 449731-85-5P 449731-86-6P
 449731-87-7P 449731-88-8P 449731-89-9P
 449731-90-2P 449731-91-3P 449731-92-4P
 449731-93-5P 449731-94-6P 449731-95-7P
 449731-96-8P 449731-97-9P 449731-98-0P
 449732-01-8P 449732-05-2P 449732-06-3P
 449732-07-4P 449732-08-5P 449732-10-9P
 449732-12-1P 449732-13-2P 449732-14-3P
 449732-15-4P 449732-16-5P 449732-17-6P
 449732-18-7P 449732-19-8P 449732-20-1P
 449732-21-2P 449732-22-3P 449732-23-4P
 449732-24-5P 449732-25-6P 449732-26-7P
 449732-27-8P 449732-28-9P 449732-29-0P
 449732-30-3P 449732-31-4P 449732-32-5P
 449732-33-6P 449732-34-7P 449732-35-8P
 449732-36-9P 449732-37-0P 449732-38-1P


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

449732-39-2P 449732-40-5P 449732-41-6P
 449732-42-7P 449732-43-8P 449732-44-9P
 449732-45-0P 449732-46-1P 449732-47-2P
 449732-48-3P 449732-49-4P 449732-50-7P
 449732-51-8P 449732-52-9P 449732-53-0P
 449732-54-1P 449732-55-2P 449732-56-3P
 449732-57-4P 449732-57-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrimidine deriva. as ERK2 inhibitors)

RN 449730-22-7 CAPLUS
 CN Pyrrolidine,
 1-[[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-23-8 CAPLUS
 CN Pyrrolidine,
 1-[[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-24-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-phenyl-4-pyrimidinyl)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-25-0 CAPLUS
 CN Morpholine, 4-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-26-1 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-27-2 CAPLUS
 CN 3-Piperidinol, 1-[[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-28-3 CAPLUS
 CN 1,4'-Bipiperidine,
 1'-[[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-29-4 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[[4-(2-amino-5-(3-methylphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-30-7 CAPLUS
 CN 1,4'-Bipiperidine, 1'-[[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-31-8 CAPLUS
CN 4-Piperidinol,
1-[[4-(2-amino-5-(3-methylphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-32-9 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-33-0 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449730-37-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 449730-38-5 CAPLUS
CN Morpholine, 4-[[4-(2-amino-5-(3-methylphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-39-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-34-1 CAPLUS
CN Pyridine,
1-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-35-2 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 449730-36-3 CAPLUS
CN Morpholine, 4-[[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 449730-40-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 449730-41-0 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-42-1 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 449730-43-2 CAPLUS
CN Pyridine, 1-[[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-44-3 CAPLUS
CN Isoquinoline, 1-[[4-[[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-45-4 CAPLUS
CN Piperazine, 1-[[4-[[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 449730-46-5 CAPLUS
CN Morpholine, 4-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-50-1 CAPLUS
CN Piperazine, 1-[[4-[[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 449730-51-2 CAPLUS
CN 3-Piperidinemethanol, 1-[[4-[[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-52-3 CAPLUS
CN Isoquinoline, 2-[[4-[[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-47-6 CAPLUS
CN 4-Piperidinol, 1-[[4-[[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-48-7 CAPLUS
CN 1,4'-Bipiperidine, 1'-[[4-[[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-49-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[2-amino-5-phenyl-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-53-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-54-5 CAPLUS
CN Pyridine, 1-[[4-[[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-55-6 CAPLUS
CN Isoquinoline, 2-[[4-[[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-56-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-57-8 CAPLUS
CN Piperazine, 1-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 449730-59-0 CAPLUS
CN Isoquinoline, 2-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-63-6 CAPLUS
CN 3-Piperidineethanol, 1-[[4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-64-7 CAPLUS
CN Piperazine, 1-[[4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 449730-65-8 CAPLUS
CN Piperazine, 1-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-60-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-61-4 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 449730-62-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[[4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-66-9 CAPLUS
CN 3-Piperidinol, 1-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-67-0 CAPLUS
CN Piperazine, 1-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 449730-68-1 CAPLUS
CN Pyridine, 1-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-fluorophenyl)-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-69-2 CAPLUS
CN Piperazine, 1-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 449730-70-5 CAPLUS
CN Piperazine, 1-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 449730-71-6 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-75-0 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 449730-76-1 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-[[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-77-2 CAPLUS
CN 1H-1,4-Diazepine, 1-[[4-[[2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-72-7 CAPLUS
CN Isoquinoline, 2-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]-1,2,3,4-tetrahydro- (9CI) (CA INDEX NAME)




RN 449730-73-8 CAPLUS
CN 3-Piperidinol, 1-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-74-9 CAPLUS
CN 3-Piperidinol, 1-[[4-[[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-78-3 CAPLUS
CN 3-Piperidinol, 1-[[4-[[2-amino-5-phenyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-79-4 CAPLUS
CN 3-Piperidineethanol, 1-[[4-[[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-80-7 CAPLUS
CN 3-Piperidineethanol, 1-[[4-[[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449730-81-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl]-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 449730-82-9 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 449730-83-0 CAPLUS
CN 4-Piperidinol, 1-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-87-4 CAPLUS
CN 1-Piperazineethanol, 4-[[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-88-5 CAPLUS
CN Piperazine, 1-acetyl-4-[[4-(2-amino-5-(3-methylphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-89-6 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-84-1 CAPLUS
CN 4-Piperidinol, 1-[[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-85-2 CAPLUS
CN 4-Piperidinol, 1-[[4-(2-amino-5-(3-chloro-2-fluorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-86-3 CAPLUS
CN Piperazine, 1-[[4-(2-amino-5-(3,4-dimethoxyphenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-90-9 CAPLUS
CN Pyrrolidine, 1-[[4-(2-amino-5-phenyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449730-91-0 CAPLUS
CN Morpholine, 4-[[4-(2-amino-5-(3-chlorophenyl)-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449731-00-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[[[2S]-tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-19-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-
 N-[(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)]




RN 449731-20-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-
 N-[(2-(dimethylamino)-2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)]




RN 449731-21-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-
 N-[(4-(methylsulfonyl)phenyl)methyl)- (9CI) (CA INDEX NAME)]

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (trifluoromethyl)phenyl]-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-26-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-methyl-4-pyrimidinyl)-N-[(2-(3-
 pyridinyl)ethyl)- (9CI) (CA INDEX NAME)]




RN 449731-30-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(5-methyl-2-(phenylamino)-4-pyrimidinyl)-N-propyl]- (9CI) (CA INDEX NAME)




RN 449731-31-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(5-methyl-2-(phenylamino)-4-pyrimidinyl)-N-(3-
 phenylpropyl)- (9CI) (CA INDEX NAME)]


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-22-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1,3-benzodioxol-5-ylmethyl)-4-[(3,5-
 dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)]




RN 449731-23-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(5-(3,5-dichlorophenyl)-2-(phenylamino)-4-
 pyrimidinyl)-N-[(2-(4-morpholinyl)-2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)]




RN 449731-24-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-(3-fluoro-5-
 pyridinyl)-2-(phenylamino)-4-pyrimidinyl)-N-[(2-(4-morpholinyl)-2-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)]

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-33-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-cyclopropyl-4-[(2-(ethylamino)-5-methyl-4-
 pyrimidinyl)- (9CI) (CA INDEX NAME)]




RN 449731-35-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(5-methyl-2-
 (phenylamino)-4-pyrimidinyl)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 449731-39-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(2-aminoethyl)-4-[(5-methyl-2-(phenylamino)-4-
 pyrimidinyl)- (9CI) (CA INDEX NAME)]




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-40-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449731-41-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 449731-42-4 CAPLUS
 CN Piperazine, 1-acetyl-4-[[4-(2-(ethylamino)-5-methyl-4-pyrimidinyl)-1H-pyrrol-2-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 449731-43-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 449731-52-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-53-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]-4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-54-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

10798766.trn


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-44-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-ethyl-4-pyrimidinyl)-N-[2-(6-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 449731-50-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-(diethylamino)ethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 449731-51-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-methyl-2-[[2-(1-piperidinyl)-4-quinazolinyl]amino]-4-pyrimidinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 449731-56-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-57-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1,3-benzodioxol-5-ylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-58-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[[4-(aminosulfonyl)phenyl]amino]-5-methyl-4-
 pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 449731-59-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-
 [[3-(phenylmethoxy)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-63-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-1-[(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-4-
 [5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-64-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[2-hydroxy-1-[[3-(trifluoromethyl)phenyl]ethyl]-
 4-[5-methyl-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 449731-65-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-1-[(3-fluoro-4-methylphenyl)-2-hydroxyethyl]-4-
 [2-[[3-(fluorophenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-60-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(trans-4-hydroxycyclohexyl)amino]-5-methyl-
 4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 449731-62-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[5-cyclopropyl-2-(phenylamino)-4-pyrimidinyl]-
 N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-66-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[3-(fluorophenyl)amino]-5-methyl-4-
 pyrimidinyl]-N-[2-hydroxy-1-[[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 449731-67-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-
 [[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-68-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [(phenylmethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-69-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3,4-dimethylphenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-70-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(4-(phenylmethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-73-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(1S)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-74-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-75-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(4-(trifluoromethoxy)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-71-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-72-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2,2,2-trifluoroethyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-76-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylpropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-77-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(cyclopropylmethyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-78-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-(methoxymethyl)-2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-79-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methoxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-80-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 449731-85-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 449731-86-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(2-hydroxy-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 449731-87-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S,2S)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-88-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-81-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(propylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-83-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(1R)-2-hydroxy-1-phenylethylamino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-89-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1R)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-90-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-91-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[1-(hydroxymethyl)cyclopropyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-92-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2R)-2-hydroxy-1-phenylethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-93-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1R)-2-hydroxy-1-methylethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-94-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2R)-2-hydroxypropyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-97-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-4-pyrimidinyl]-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 449731-98-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-4-pyrimidinyl]-N-[(1R)-2-hydroxy-1-methyl-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-01-8 CAPLUS
 CN Benzeneacetic acid, α-[[[4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-1H-pyrrol-2-yl]carbonyl]amino]-, methyl ester, (uS)- (9CI) (CA INDEX NAME)

10798766.trn


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 449731-95-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(2S)-2-hydroxypropyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-96-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2-hydroxycyclohexyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 449732-05-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(2-hydroxy-1-(3-pyridinyl)ethyl)- (9CI) (CA INDEX NAME)




RN 449732-06-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-(hydroxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-07-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-08-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((ethylamino)-5-methyl-4-pyrimidinyl)-N-[(1-(3-fluorophenyl)-2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 449732-10-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((ethylamino)-5-methyl-4-pyrimidinyl)-N-[(1-(2-fluorophenyl)-2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 449732-12-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-cyclopropyl-1-

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-15-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-cyclopropyl-1-(hydroxymethyl)-2-methylpropyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-16-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((ethylamino)-5-methyl-4-pyrimidinyl)-N-(2-oxo-1-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 449732-17-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((ethylamino)-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10798766.trn


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (hydroxymethyl)ethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-13-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2,3-dimethylphenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-14-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((ethoxyamino)-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-18-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[3-(fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-19-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[2-chlorophenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-20-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-((1S)-2-hydroxy-1-phenylethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-21-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-(trifluoromethyl)phenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-24-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-25-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-(methoxyamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-22-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(2-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-23-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[2-(cyclopropylamino)-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-26-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(1-methylethoxy)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-27-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[[3-(dimethylamino)phenyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 449732-28-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-[(2-hydroxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-29-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-30-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(2,3-dimethylphenyl)amino]-5-methyl-4-

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-33-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-34-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(3-pyridinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-31-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(3-fluorophenyl)amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-32-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(acetylamino)-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-35-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[[(2S)-tetrahydro-2-furanyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-36-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[[[(2R)-tetrahydro-2-furanyl]methyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-37-0 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[4-{5-[[[(1S)-2-hydroxy-1-phenylethyl]amino]carbonyl]-1H-pyrrol-3-yl]-5-methyl-2-pyrimidinyl]-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-38-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-{5-methyl-2-[(3-pyridinylmethyl)amino]-4-pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE
 RN 449732-41-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-{2-[(1S)-2-hydroxy-1-methylethyl]amino}-5-methyl-4-pyrimidinyl-N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-42-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-{5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-39-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-{2-[(cyclopropylmethoxy)amino]-5-methyl-4-pyrimidinyl}-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-40-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-{2-(3-isoxazolylamino)-5-methyl-4-pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-43-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-{5-methyl-2-[(2-methylphenyl)amino]-4-pyrimidinyl}- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-44-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-{2-[(2-hydroxyethoxy)amino]-5-methyl-4-pyrimidinyl}-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-45-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(1S)-2-hydroxy-1-phenylethyl]-5-methyl-2-pyrimidinyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-46-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(2-(trifluoromethyl)phenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 449732-49-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]-5-methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-50-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(1S)-1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-47-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-(4-morpholinylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-48-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-[(5-methyl-3-isoxazolyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-51-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449732-52-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-53-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(1S)-2-hydroxy-1-(3-methylphenyl)ethyl]-4-[2-
 [(1S)-1-(hydroxymethyl)propyl]amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 449732-54-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[2-[(2-hydroxy-1-(hydroxymethyl)ethyl)amino]-5-
 methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-57-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-(cyanoamino)-5-methyl-4-pyrimidinyl]-N-
 [(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449733-07-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(3-chlorophenyl)-4-pyrimidinyl]-N-
 methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



IT 338403-73-9P 449730-58-9P 449730-92-1P
 449730-93-2P 449730-94-3P 449730-95-4P
 449730-96-5P 449730-97-6P 449730-98-7P
 449730-99-8P 449731-01-5P 449731-02-6P
 449731-03-7P 449731-04-8P 449731-05-9P
 449731-06-0P 449731-07-1P 449731-08-2P
 449731-09-3P 449731-10-6P 449731-11-7P
 449731-12-8P 449731-13-9P 449731-14-0P
 449731-15-1P 449731-16-2P 449731-17-3P


10798766.trn

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449732-55-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-[(1S)-1-(hydroxymethyl)propyl]amino]-5-
 methyl-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 449732-56-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[5-methyl-2-
 [(2-methylcyclopropyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


449731-18-4P 449731-25-3P 449731-27-5P
 449731-28-6P 449731-29-7P 449731-32-2P
 449731-34-4P 449731-37-7P 449731-38-8P
 449731-45-7P 449731-46-8P 449731-47-9P
 449731-48-0P 449731-49-1P 449731-55-9P
 449731-61-7P 449731-82-2P 449731-84-4P
 449731-99-1P 449732-00-7P 449732-02-9P
 449732-03-0P 449732-04-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
 study); PREP (Preparation); USES (Uses)
 (prepn. of pyrimidine derivs. as ERK2 inhibitors)


RN 338403-73-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-(2-amino-5-phenyl-4-pyrimidinyl)-N,N-dimethyl-
 (9CI) (CA INDEX NAME)



RN 449730-58-9 CAPLUS
 CN 1H-1,4-Diazepine, 1-[[4-[2-amino-5-(3-methylphenyl)-4-pyrimidinyl]-1H-
 pyrrol-2-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)




RN 449730-92-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-
 (phenylmethyl)- (9CI) (CA INDEX NAME)




RN 449730-93-2 CAPLUS

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-94-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449730-95-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-96-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-01-5 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1R)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-02-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(1S)-3-hydroxy-1-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-03-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-(2,5-diamino-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449730-97-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-98-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449730-99-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-5-methyl-4-pyrimidinyl)-N-[(2R)-tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-04-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-(methylamino)-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-05-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-(acetamino)-2-amino-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-06-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[2-amino-5-[(methylamino)carbonylamino]-4-pyrimidinyl]-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-07-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-amino-5-hydroxy-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-08-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-[(methylamino)methyl]-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-09-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-(hydroxymethyl)-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-13-9 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-(methylsulfonyl)-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-14-0 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-amino-5-(hydroxymethyl)-4-pyrimidinyl)-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-15-1 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-(cyclohexylamino)-5-methyl-4-pyrimidinyl)-N-[(3,4-difluorophenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-10-6 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, N-[(3-chloro-4-fluorophenyl)methyl]-4-[(2-(cyclohexylamino)-5-[(methylamino)carbonylamino]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 449731-11-7 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[(2-(acetylamino)-5-[(methylamino)carbonylamino]-4-pyrimidinyl)-N-[(3-chloro-4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-12-8 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 N-[(3-chloro-4-fluorophenyl)methyl]-4-[5-hydroxy-


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-16-2 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 449731-17-3 CAPLUS
 CN 1H-Pyrrole-2-carboxamide, 4-[5-(3,5-dichlorophenyl)-2-(phenylamino)-4-pyrimidinyl)-N-[(3-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 449731-18-4 CAPLUS
 CN 1H-Pyrrole-2-carboxamide,
 4-[(2-amino-5-(3,5-dichlorophenyl)-4-pyrimidinyl)-N-[(1R)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-25-3 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((2-amino-5-propyl-4-pyrimidinyl)-N-(2-(3-pyridinyl)ethyl))- (9CI) (CA INDEX NAME)




RN 449731-27-5 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((5-methyl-2-(methylamino)-4-pyrimidinyl)-N-(2-(3-pyridinyl)ethyl))- (9CI) (CA INDEX NAME)




RN 449731-28-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((2-(methylamino)-4-pyrimidinyl)-N-(2-(3-pyridinyl)ethyl))- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-37-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((2-(ethylamino)-4-pyrimidinyl)-N-(4-methylcyclohexyl))- (9CI) (CA INDEX NAME)




RN 449731-38-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((5-ethyl-2-(phenylamino)-4-pyrimidinyl)-N-(1-methylethyl))- (9CI) (CA INDEX NAME)




RN 449731-45-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((5-methyl-2-(phenylamino)-4-pyrimidinyl)-N-(2-phenoxyethyl))- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-29-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-([2-(dimethylamino)ethyl]-4-[2-(ethylamino)-5-methyl-4-pyrimidinyl])- (9CI) (CA INDEX NAME)




RN 449731-32-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((2-(ethylamino)-5-methyl-4-pyrimidinyl)-N-(1-naphthalenylmethyl))- (9CI) (CA INDEX NAME)




RN 449731-34-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((2-(ethylamino)-4-pyrimidinyl)-N-([2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(1-naphthalenylmethyl))- (9CI) (CA INDEX NAME)


L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 449731-46-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-((5-methyl-2-(phenylamino)-4-pyrimidinyl)-N-(1-methyl-3-phenylpropyl))- (9CI) (CA INDEX NAME)




RN 449731-47-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-([2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(1-methyl-3-phenylpropyl))- (9CI) (CA INDEX NAME)



RN 449731-48-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-([2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-(1-methyl-3-phenylpropyl))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-49-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-[(1H-imidazol-4-yl)methyl]ethyl]-4-[5-methyl-2-(methylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449731-55-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[(1S)-2-hydroxy-1-phenylethyl]-4-[2-[(3-methoxyphenyl)amino]-5-methyl-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449731-99-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-(2-hydroxy-2-phenylethyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 449732-00-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(2S)-2-hydroxy-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 449732-02-9 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 449731-61-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-cyclohexyl-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449731-82-2 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[5-(hydroxymethyl)-2-(phenylamino)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 449731-84-4 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-methyl-4-pyrimidinyl]-N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 449732-03-0 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-(2-amino-4-pyrimidinyl)-N-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 449732-04-1 CAPLUS
CN 1H-Pyrrole-2-carboxamide, 4-[2-(ethylamino)-5-(methoxymethyl)-4-pyrimidinyl]-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Page 51

=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
54.22	222.25

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-6.75	-6.75

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:49:26 ON 14 DEC 2006

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**